Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T08856
|
||||
| Former ID |
TTDR01266
|
||||
| Target Name |
Neutrophil collagenase
|
||||
| Gene Name |
MMP8
|
||||
| Synonyms |
MMP-8; Matrix metalloproteinase-8; PMNL collagenase; PMNL-CL; MMP8
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Multiple scierosis [ICD9: 340; ICD10: G35] | ||||
| Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
| Function |
Can degrade fibrillar type I, II, and III collagens.
|
||||
| BioChemical Class |
Peptidase
|
||||
| Target Validation |
T08856
|
||||
| UniProt ID | |||||
| EC Number |
EC 3.4.24.34
|
||||
| Sequence |
MFSLKTLPFLLLLHVQISKAFPVSSKEKNTKTVQDYLEKFYQLPSNQYQSTRKNGTNVIV
EKLKEMQRFFGLNVTGKPNEETLDMMKKPRCGVPDSGGFMLTPGNPKWERTNLTYRIRNY TPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGIL AHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYA FRETSNYSLPQDDIDGIQAIYGLSSNPIQPTGPSTPKPCDPSLTFDAITTLRGEILFFKD RYFWRRHPQLQRVEMNFISLFWPSLPTGIQAAYEDFDRDLIFLFKGNQYWALSGYDILQG YPKDISNYGFPSSVQAIDAAVFYRSKTYFFVNDQFWRYDNQRQFMEPGYPKSISGAFPGI ESKVDAVFQQEHFFHVFSGPRYYAFDLIAQRVTRVARGNKWLNCRYG |
||||
| Drugs and Mode of Action | |||||
| Inhibitor | 1-Hydroxyamine-2-Isobutylmalonic Acid | Drug Info | [551393] | ||
| 2-(biphenyl-4-ylsulfonamido)pentanedioic acid | Drug Info | [529392] | |||
| 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide | Drug Info | [530402] | |||
| 2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID | Drug Info | [551374] | |||
| 2-Thiomethyl-3-Phenylpropanoic Acid | Drug Info | [551393] | |||
| 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol | Drug Info | [525535] | |||
| 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol | Drug Info | [525535] | |||
| 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol | Drug Info | [525535] | |||
| 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol | Drug Info | [525535] | |||
| 3-AMINO-AZACYCLOTRIDECAN-2-ONE | Drug Info | [551374] | |||
| 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid | Drug Info | [529392] | |||
| BB-1101 | Drug Info | [525644] | |||
| Glycinamid | Drug Info | [551393] | |||
| IK-682 | Drug Info | [526446] | |||
| ILOMASTAT | Drug Info | [551294] | |||
| METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID | Drug Info | [551374] | |||
| MMI270 | Drug Info | [525642] | |||
| N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide | Drug Info | [530402] | |||
| Ro-37-9790 | Drug Info | [551326] | |||
| SC-44463 | Drug Info | [526154] | |||
| SL422 | Drug Info | [526113] | |||
| [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid | Drug Info | [530402] | |||
| Modulator | CIPEMASTAT | Drug Info | [532656] | ||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| References | |||||
| Ref 532656 | Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. | ||||
| Ref 541601 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6466). | ||||
| Ref 542432 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7409). | ||||
| Ref 544872 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001387) | ||||
| Ref 525535 | Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60.Synthesis and identification of conformationally constrained selective MMP inhibitors. | ||||
| Ref 525642 | J Med Chem. 1999 Nov 4;42(22):4547-62.Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. | ||||
| Ref 525644 | J Med Chem. 1999 Nov 18;42(23):4890-908.New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. | ||||
| Ref 526113 | Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. | ||||
| Ref 526154 | J Med Chem. 2001 Oct 11;44(21):3347-50.Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. | ||||
| Ref 526446 | J Med Chem. 2002 Nov 7;45(23):4954-7.Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. | ||||
| Ref 529392 | Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. Epub 2008 Mar 8.Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. | ||||
| Ref 530402 | J Med Chem. 2009 Oct 22;52(20):6347-61.Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. | ||||
| Ref 532656 | Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. | ||||
| Ref 551294 | Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.